Skip to main content
Leiden University
Scholarly Publications
Home
Submit
About
Select Collection
All collections
Academic speeches
Dissertations
Faculty of Archaeology
Faculty of Governance and Global Affairs
Faculty of Humanities
Faculty of Science
Faculty of Social and Behavioural Sciences
Leiden Journals, Conference Proceedings and Books
Leiden Law School
Leiden University Press
Medicine / Leiden University Medical Centre (LUMC)
Research output UL
Search box
Your Search
Enabled Filters
(-)
= Groot, S.M. de
Sort Options
Date (year)
Author / Creator
Title
Refine Results
Resource Type
Article / Letter to editor
(8)
+
-
Availability
Metadata Only
(8)
+
-
Creation Date
2014
(3)
+
-
2015
(3)
+
-
Faculty
Leiden University Medical Center (LUMC)
(8)
+
-
Collection
Medicine / Leiden University Medical Centre (LUMC)
(8)
+
-
Topic
Metastatic breast cancer
(2)
+
-
Author
Groot, S.M. de
(8)
+
-
Tinteren, H. van
(7)
+
-
Braun, J.J.
(5)
+
-
Graaf, H. de
(5)
+
-
Honkoop, A.H.
(5)
+
-
Jager, A.
(5)
+
-
Kroep, J.R.
(5)
+
-
Linn, S.C.
(5)
+
-
M. los
(5)
+
-
Smorenburg, C.H.
(5)
+
-
Bosch, J. van den
(4)
+
-
E. boven
(4)
+
-
Lam, S.W.
(4)
+
-
Portielje, J.E.A.
(4)
+
-
Bos, M.M.E.M.
(3)
+
-
Jongh, F.E. de
(3)
+
-
Leeuwen-Stok, A.E. van
(3)
+
-
Maartense, E.
(3)
+
-
Nortier, J.W.R.
(3)
+
-
Seynaeve, C.
(3)
+
-
Velden, A.M.T. van der
(3)
+
-
Berends, J.
(2)
+
-
Boer, M.O. den
(2)
+
-
Braun, H.J.
(2)
+
-
Douma, J.
(2)
+
-
Hamaker, M.E.
(2)
+
-
Jeurissen, F.
(2)
+
-
Nota, N.M.
(2)
+
-
Riel, J.M.G.H. van
(2)
+
-
Tanis, B.
(2)
+
-
Terwogt, J.M.M.
(2)
+
-
Tije, A.J. ten
(2)
+
-
Wymenga, A.N.M.
(2)
+
-
Show more
Language
en
(8)
+
-
Search results
(1 - 8 of 8)
show grid
show list
save search
Genetic polymorphisms (SNPs) as predictive markers for paclitaxel-induced peripheral neuropathy (PNP) and capecitabine-induced hand-foot syndrome (HFS) in HER-2 negative metastatic breast cancer patients
Plasma biomarker analysis in patients with HER2-negative locally recurrent or metastatic breast cancer (LR/MBC) treated with first-line bevacizumab (A) and paclitaxel (T) without or with capecitabine (X)
Results from a randomized phase II study of the Dutch Breast Cancer Research Group (BOOG 2008-03): Concomitant trastuzumab, bevacizumab and paclitaxel (HAT) versus trastuzumab and bevacizumab, followed by trastuzumab, bevacizumab and paclitaxel (HA- HAT)
Paclitaxel and bevacizumab with or without capecitabine as first-line treatment for HER2-negative locally recurrent or metastatic breast cancer: A multicentre, open-label, randomised phase 2 trial
A randomized phase III study comparing pegylated liposomal doxorubicin with capecitabine as first-line chemotherapy in elderly patients with metastatic breast cancer: results of the OMEGA study of the Dutch Breast Cancer Research Group BOOG
Baseline comprehensive geriatric assessment is associated with toxicity and survival in elderly metastatic breast cancer patients receiving single-agent chemotherapy: Results from the OMEGA study of the Dutch Breast Cancer Trialists' Group
Plasma VEGF-a, angiopoietin-2 (ANG2) and soluble(s)TIE2 in patients (pts) with HER2-negative locally recurrent or metastatic breast cancer (LR/MBC) treated with first-line bevacizumab (A) and paclitaxel (T) without or with capecitabine (X)
Feasibility and Toxicities Associated with PEG Doxo Versus Capecitabine as First-line Chemotherapy in Elderly Metastatic Breast Cancer (MBC) Patients; Results From the Randomized OMEGA Study of the Dutch Breast Cancer Trialists' Group (BOOG)